Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Alogliptin benzoate |
Is a |
False |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing alogliptin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing alogliptin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Alogliptin benzoate |
Is modification of (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Alogliptin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing only alogliptin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Alogliptin (as alogliptin benzoate) 6.25 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Alogliptin (as alogliptin benzoate) 25 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing alogliptin and metformin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin and metformin only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing alogliptin and metformin in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin and metformin only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin (as alogliptin benzoate) 12.5 mg and metformin hydrochloride 850 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin (as alogliptin benzoate) 12.5 mg and metformin hydrochloride 1 g oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin (as alogliptin benzoate) 12.5 mg and metformin hydrochloride 500 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing alogliptin and pioglitazone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin and pioglitazone only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing alogliptin and pioglitazone in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin and pioglitazone only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 45 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 15 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely alogliptin (as alogliptin benzoate) 25 milligram and pioglitazone (as pioglitazone hydrochloride) 30 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin (as alogliptin benzoate) 12.5 mg and pioglitazone (as pioglitazone hydrochloride) 30 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely alogliptin (as alogliptin benzoate) 12.5 milligram and pioglitazone (as pioglitazone hydrochloride) 15 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Alogliptin (as alogliptin benzoate) 12.5 mg and pioglitazone (as pioglitazone hydrochloride) 45 mg oral tablet |
Has basis of strength substance (attribute) |
True |
Alogliptin |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |